03/04/2007 (Agence Europe) - The European Medicines Agency (EMEA) has recommended new restrictions on the use of Ketek by the laboratory Sanofi-Aventis. At the end of its meeting on 19-22 March, EMEA declared that in the indications for bronchitis, sinusitis and tonsillitis/pharyngitis, telithromycin should only be used for infections caused by bacterial strains that are suspected or proven to be resistant to or which cannot be treated with macrolide or beta-lactam antibiotics. These...